Skip to main content
. 2015 Apr 16;4(4):243–254. doi: 10.1002/psp4.32

Figure 3.

Figure 3

Case study 2. Given the proposed scaling approach and parameter ranges (Table 3), compounds (Cmps) 2A–2D are likely to have a human dose below 500 mg, and Cmp 2E is likely to have a dose below 1,000 mg for a model with steady-state concentration (Css)-driven effect (a). If the effect is driven by the minimal effective concentration, Cmp 2A is likely to have a human dose below 500 mg, whereas the others are not (b); and assuming this model is medium likelihood that Cmp 2A can be administered once daily (c).